Kaijie, a foreign medical company with advanced medical technology, is trying to squeeze into the huge Chinese pharmaceutical market, but the current progress is far below its expectations.
In October, Kaijie brought the Nobel Prize-winning research, HPV molecular detection technology for cervical cancer, to host the 2011 International Cervical Cancer Summit in Beijing to discuss the superiority of HPV molecular detection technology in cervical cancer screening. inferior.
Prior to this, the penetration rate of HPV molecular detection technology in the Chinese market was not high.
In 2009, the country formally included cervical cancer into two cancer screenings and proposed a plan for free screening of 10 million rural women. Among the detection methods it adopted, there was no HPV molecular detection technology, but a cheap Pap smear method.
Kaijie hopes to use the more advanced HPV molecular detection technology in China instead of the Pap smear method. However, due to the price threshold, the current progress is not smooth.
According to Professor Qiao Youlin, professor of epidemiology at the Chinese Academy of Sciences Cancer Hospital, as early as five years ago, the National Center for Disease Prevention of the Ministry of Health had already conducted pilot projects in the country to study methods for controlling cervical cancer screening programs. However, the state can only undertake inspections for each person. The cost of 50 yuan, this fee standard has continued to this day.
Kaijie’s sources stated that the cost of HPV molecular testing is approximately between 200 and 300 RMB. “If you consider that HPV testing has no problem, you can no longer check in 3-5 years, then this cost and Pap smear test It is basically the same."
Kaijie hopes to convey the above ideas to the Chinese government and take the opportunity to enter the government's screening for cervical cancer. Shi Chenyang, President of Asia Pacific of Kaijie Company, said in an interview with reporters that he hopes to expand cooperation with the government and promote the process of Chinese medical reform.
He said that every year, there are millions of women in China who have accepted Kaijie's HPV screening, but he did not explain how many people in China pay for their own tests. Our reporter was informed that Kaijie has been providing free cervical cancer HPV molecular testing to the China Cancer Foundation in recent years.
In fact, from the start of the new medical reform in 2009, more "safe, effective, convenient, and cheaper" drugs were included in the government-purchased pharmaceutical products, while drugs from foreign pharmaceutical companies were often excluded from government procurement due to high pricing. Outside the range.
In an interview with reporters, Guo Fanli, a research fellow in the pharmaceutical industry of China Investment Advisors Co., Ltd., said that Kai Jie encountered a number of problems encountered by foreign pharmaceutical companies in China - high pricing, resulting in low market promotion.
However, this does not affect the attractiveness of the Chinese market for foreign investment. Shi Chenyang pointed out that in the past five years, the Asia-Pacific region's contribution to the entire company has shown steady growth. In this short period of several years, the region’s growth has exceeded three times, of which the Chinese market has maintained two figures for several consecutive years. The growth, "application testing market growth rate is significantly faster than the detection of cervical cancer HPV as the representative of the molecular detection and clinical testing market," he believes that China will be the company's fastest-growing region in the future. According to Kejie's predictions, the market potential for HPV molecular testing reaches $1 billion.
Although there is no exact data, more and more foreign-funded pharmaceutical companies are trying to enter the Chinese market, and Chinese domestic companies will face increasing competitive pressure. Guo Fanli suggested that domestic pharmaceutical companies need to change their thinking to make raw materials with lower profits. Pharmaceutical production has gradually transitioned to the production of higher profitable formulations. Only in this way can it meet the development trend of the global pharmaceutical industry. (
In October, Kaijie brought the Nobel Prize-winning research, HPV molecular detection technology for cervical cancer, to host the 2011 International Cervical Cancer Summit in Beijing to discuss the superiority of HPV molecular detection technology in cervical cancer screening. inferior.
Prior to this, the penetration rate of HPV molecular detection technology in the Chinese market was not high.
In 2009, the country formally included cervical cancer into two cancer screenings and proposed a plan for free screening of 10 million rural women. Among the detection methods it adopted, there was no HPV molecular detection technology, but a cheap Pap smear method.
Kaijie hopes to use the more advanced HPV molecular detection technology in China instead of the Pap smear method. However, due to the price threshold, the current progress is not smooth.
According to Professor Qiao Youlin, professor of epidemiology at the Chinese Academy of Sciences Cancer Hospital, as early as five years ago, the National Center for Disease Prevention of the Ministry of Health had already conducted pilot projects in the country to study methods for controlling cervical cancer screening programs. However, the state can only undertake inspections for each person. The cost of 50 yuan, this fee standard has continued to this day.
Kaijie’s sources stated that the cost of HPV molecular testing is approximately between 200 and 300 RMB. “If you consider that HPV testing has no problem, you can no longer check in 3-5 years, then this cost and Pap smear test It is basically the same."
Kaijie hopes to convey the above ideas to the Chinese government and take the opportunity to enter the government's screening for cervical cancer. Shi Chenyang, President of Asia Pacific of Kaijie Company, said in an interview with reporters that he hopes to expand cooperation with the government and promote the process of Chinese medical reform.
He said that every year, there are millions of women in China who have accepted Kaijie's HPV screening, but he did not explain how many people in China pay for their own tests. Our reporter was informed that Kaijie has been providing free cervical cancer HPV molecular testing to the China Cancer Foundation in recent years.
In fact, from the start of the new medical reform in 2009, more "safe, effective, convenient, and cheaper" drugs were included in the government-purchased pharmaceutical products, while drugs from foreign pharmaceutical companies were often excluded from government procurement due to high pricing. Outside the range.
In an interview with reporters, Guo Fanli, a research fellow in the pharmaceutical industry of China Investment Advisors Co., Ltd., said that Kai Jie encountered a number of problems encountered by foreign pharmaceutical companies in China - high pricing, resulting in low market promotion.
However, this does not affect the attractiveness of the Chinese market for foreign investment. Shi Chenyang pointed out that in the past five years, the Asia-Pacific region's contribution to the entire company has shown steady growth. In this short period of several years, the region’s growth has exceeded three times, of which the Chinese market has maintained two figures for several consecutive years. The growth, "application testing market growth rate is significantly faster than the detection of cervical cancer HPV as the representative of the molecular detection and clinical testing market," he believes that China will be the company's fastest-growing region in the future. According to Kejie's predictions, the market potential for HPV molecular testing reaches $1 billion.
Although there is no exact data, more and more foreign-funded pharmaceutical companies are trying to enter the Chinese market, and Chinese domestic companies will face increasing competitive pressure. Guo Fanli suggested that domestic pharmaceutical companies need to change their thinking to make raw materials with lower profits. Pharmaceutical production has gradually transitioned to the production of higher profitable formulations. Only in this way can it meet the development trend of the global pharmaceutical industry. (
JRT usb interface distance sensor board adds a USB port to a Laser Distance Sensor, inexpensive laser distance measurement sensors, allowing customers directly using GBeacon-2.3-Fx.exe software to control the rangefinder sensor. Usb laser distance sensors are the the most popular model devices, it works by measuring the phase of an visible-red laser beam that reflects on the target. Usually, customers would like to choose CH341SER.EXE version to test.
USB Laser Distance Sensor,Distance Sensor,Laser Distance Sensor,Distance Measurement Sensors
Chengdu JRT Meter Technology Co., Ltd , https://www.cdtoflidarsensor.com